Regarding the mechanism of action of antileprotic drugs, all of the following statements are TRUE EXCEPT:

## Analysis of Antileprotic Drug Mechanisms ### Correct Statements (Options A, C, D) **Option A — Rifampicin:** **Key Point:** Rifampicin inhibits the beta-subunit of bacterial DNA-dependent RNA polymerase, thereby blocking mRNA synthesis. It is bactericidal against *M. leprae* and is the most potent antileprotic drug, forming the backbone of all WHO-MDT regimens. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.)* **Option C — Clofazimine:** **Key Point:** Clofazimine is a redox-active riminophenazine dye that generates reactive oxygen species (ROS), causing oxidative damage to mycobacterial DNA and cell membranes. It also has immunomodulatory and anti-inflammatory effects, making it particularly useful in managing erythema nodosum leprosum (ENL). *(KD Tripathi, 8th ed.)* **Option D — Ofloxacin:** **Key Point:** Ofloxacin is NOT a first-line agent and is NOT preferred over rifampicin in any standard leprosy regimen. Rifampicin remains the cornerstone of all WHO-MDT regimens for both paucibacillary (PB) and multibacillary (MB) leprosy. Ofloxacin is reserved for second-line or alternative therapy when rifampicin is contraindicated or in drug-resistant cases. This statement is TRUE (correctly identifies ofloxacin's limited role), making it a correct statement in context — wait, see below. ### Incorrect Statement (Option B) — The Answer **Option B — Dapsone:** **Warning:** This statement is **FALSE**. Dapsone does NOT inhibit dihydrofolate reductase (DHFR). Dapsone is a sulfone that acts as a **competitive inhibitor of dihydropteroate synthase (DHPS)**, competing with para-aminobenzoic acid (PABA) to block the incorporation of PABA into dihydropteroic acid — an early step in folate synthesis. This is analogous to the mechanism of **sulfonamides**, not methotrexate. **Methotrexate**, by contrast, inhibits **dihydrofolate reductase (DHFR)** — a different enzyme acting at a later step in the folate pathway. Comparing dapsone to methotrexate is therefore mechanistically incorrect. | Drug | Enzyme Inhibited | Step in Folate Pathway | |---|---|---| | Dapsone (sulfone) | Dihydropteroate synthase (DHPS) | Early — blocks PABA incorporation | | Sulfonamides | Dihydropteroate synthase (DHPS) | Early — blocks PABA incorporation | | Methotrexate | Dihydrofolate reductase (DHFR) | Late — blocks DHF → THF conversion | | Trimethoprim | Dihydrofolate reductase (DHFR) | Late — blocks DHF → THF conversion | **High-Yield:** Dapsone's mechanism is analogous to sulfonamides (DHPS inhibition), NOT to methotrexate (DHFR inhibition). This is a classic NEET PG distinction. *(KD Tripathi, Essentials of Medical Pharmacology, 8th ed.; Goodman & Gilman's Pharmacological Basis of Therapeutics, 13th ed.)* **Clinical Pearl:** The combination of rifampicin (bactericidal, RNA polymerase inhibitor), dapsone (DHPS inhibitor, bacteriostatic), and clofazimine (ROS generator, anti-inflammatory) in MB leprosy targets three distinct mechanisms, minimizing the risk of drug resistance.